Ocular Therapeutix (NASDAQ:OCUL – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $28.00 price target on the biopharmaceutical company’s stock. HC Wainwright‘s price objective would indicate a potential upside of 365.89% from the company’s current price.
Several other research firms also recently weighed in on OCUL. UBS Group began coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They set a “buy” rating and a $14.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. Wall Street Zen downgraded shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Saturday. Finally, Chardan Capital reissued a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.83.
Get Our Latest Stock Report on OCUL
Ocular Therapeutix Price Performance
Shares of OCUL stock opened at $6.01 on Tuesday. Ocular Therapeutix has a fifty-two week low of $5.94 and a fifty-two week high of $16.44. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -4.12 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.03 and a current ratio of 9.12. The stock’s 50-day simple moving average is $7.90 and its 200-day simple moving average is $8.89.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The company had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business’s revenue was down 11.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.38) EPS. As a group, equities analysts forecast that Ocular Therapeutix will post -1.61 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Todd Anderman sold 11,984 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider owned 140,484 shares in the company, valued at approximately $1,024,128.36. This represents a 7.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $70,429.50. Following the transaction, the insider directly owned 254,388 shares of the company’s stock, valued at $1,793,435.40. This represents a 3.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 98,090 shares of company stock valued at $787,920. 3.10% of the stock is owned by insiders.
Institutional Trading of Ocular Therapeutix
Several large investors have recently made changes to their positions in OCUL. Commonwealth Equity Services LLC increased its stake in shares of Ocular Therapeutix by 8.1% in the third quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,575 shares during the period. Principal Financial Group Inc. lifted its position in Ocular Therapeutix by 24.1% during the first quarter. Principal Financial Group Inc. now owns 13,623 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 2,642 shares during the period. NewEdge Advisors LLC lifted its position in Ocular Therapeutix by 21.7% during the second quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,979 shares during the period. Raiffeisen Bank International AG boosted its holdings in Ocular Therapeutix by 5.3% in the second quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Ocular Therapeutix in the second quarter valued at $51,000. 59.21% of the stock is owned by hedge funds and other institutional investors.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
Featured Articles
- Five stocks we like better than Ocular Therapeutix
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
